- Home
- ALNY vs SLF Comparison
ALNY vs SLF Comparison
Compare ALNY & SLF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALNY
- SLF
- Stock Information
- Founded
- ALNY 2002
- SLF 1871
- Country
- ALNY United States
- SLF Canada
- Employees
- ALNY N/A
- SLF N/A
- Industry
- ALNY Biotechnology: Pharmaceutical Preparations
- SLF Advertising
- Sector
- ALNY Health Care
- SLF Consumer Discretionary
- Exchange
- ALNY Nasdaq
- SLF Nasdaq
- Market Cap
- ALNY 40.4B
- SLF 37.5B
- IPO Year
- ALNY 2004
- SLF N/A
- Fundamental
- Price
- ALNY $320.87
- SLF $61.59
- Analyst Decision
- ALNY Strong Buy
- SLF Buy
- Analyst Count
- ALNY 24
- SLF 1
- Target Price
- ALNY $341.91
- SLF $88.00
- AVG Volume (30 Days)
- ALNY 863.4K
- SLF 460.1K
- Earning Date
- ALNY 07-31-2025
- SLF 08-07-2025
- Dividend Yield
- ALNY N/A
- SLF 3.92%
- EPS Growth
- ALNY N/A
- SLF 3.59
- EPS
- ALNY N/A
- SLF 3.81
- Revenue
- ALNY $2,348,099,000.00
- SLF $23,434,793,186.00
- Revenue This Year
- ALNY $30.77
- SLF N/A
- Revenue Next Year
- ALNY $30.51
- SLF $4.18
- P/E Ratio
- ALNY N/A
- SLF $16.17
- Revenue Growth
- ALNY 17.21
- SLF 7.25
- 52 Week Low
- ALNY $205.87
- SLF $46.41
- 52 Week High
- ALNY $333.70
- SLF $66.81
- Technical
- Relative Strength Index (RSI)
- ALNY 57.52
- SLF 35.06
- Support Level
- ALNY $314.10
- SLF $64.31
- Resistance Level
- ALNY $328.99
- SLF $66.81
- Average True Range (ATR)
- ALNY 9.40
- SLF 0.93
- MACD
- ALNY -1.23
- SLF -0.53
- Stochastic Oscillator
- ALNY 52.48
- SLF 0.57
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
About SLF Sun Life Financial Inc.
Sun Life Financial is one of the Big Three Canadian life insurers. The Canadian business contributed around 38% of adjusted earnings. In that segment, the firm provides health, life insurance, and annuity products to individual and group customers. Its US business is mostly group health and contributed about 20% of the firm's adjusted earnings in 2024. Sun Life also offers life insurance and wealth products in several Asian markets with a strong presence in Hong Kong and the Philippines. The Asia segment contributed around 18% of adjusted 2024 earnings. Its asset management business had around CAD 1.1 trillion total assets under management or administration at the end of 2024 and represents around 34% of the firm's earnings.